CNTO 148

개요The proinflammatory cytokine tumor necrosis factor-alpha (TNF-α) has been implicated as the primary mediator of articular inflammation in diseases such as RA, PsA, and AS. Targeting TNF-a has been a successful strategy in the intervention of a range of immunoinflammatory disorders. Biologics have risen to the forefront of TNF-α blockade with infliximab, a chimeric monoclonal antibody (mAb), and etanercept, a fusion protein comprised of the ligand-binding segment of the soluble TNF receptor, reaching the market in the late 1990s for the initial indication of RA. Since then, their use has expanded to other diseases of inflammatory etiology, and two additional TNF-α inhibitors have joined the competition. Golimumab, a human anti-TNF-α mAb that binds to both soluble and transmembrane forms of TNF-a, is the first once-monthly subcutaneous agent to enter the market and is currently approved for the treatment of RA in combination with methotrexate (MTX), PsA alone or in combination with MTX, and AS. .

용도Treatment of allergic asthma.